A second biosimilar to infliximab, marketed as Remicade by Johnson & Johnson, has received FDA approval. Infliximab-abda (Renflexis) was developed by Samsung Bioepis/Merck and has been approved for ...
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for ...
Celltrion Healthcare is continuing to make the case for switching from intravenous to subcutaneous formulations of infliximab, with the latest data drop suggesting there may be benefits beyond ...
INCHEON, South Korea--(BUSINESS WIRE)--Today, Celltrion Healthcare announced two new data sets on the SC formulation of infliximab, Remsima ® (CT-P13) in IBD, at the European Crohn’s and Colitis ...
Infliximab is a monoclonal antibody that is administered intravenously to treat patients with chronic inflammatory diseases including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, plaque ...
JERSEY CITY, N.J., May 21, 2024 /PRNewswire/ -- Celltrion USA announced today positive two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) for ZYMFENTRA™ (infliximab-dyyb) ...
On October 23, 2023, Celltrion announced FDA approval for ZYMFENTRA (infliximab-dyyb), a subcutaneous formulation for maintenance therapy for patients with moderately to severely active ulcerative ...
Findings from the extended LIBERTY studies and associated post-hoc analysis support the long-term efficacy and safety of ZYMFENTRA™, the first and only FDA-approved subcutaneous infliximab [1],[2] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results